You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Litigation Details for Mellaconic IP LLC v. TimeClock Plus, LLC. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Mellaconic IP LLC v. TimeClock Plus, LLC.
The small molecule drug covered by the patents cited in this case is ⤷  Try for Free .
Biologic Drugs cited in Mellaconic IP LLC v. TimeClock Plus, LLC.
The biologic drugs covered by the patents cited in this case are ⤷  Try for Free and ⤷  Try for Free .

Mellaconic IP LLC v. TimeClock Plus, LLC: A Comprehensive Litigation Summary and Analysis

Case Overview

Mellaconic IP LLC v. TimeClock Plus, LLC is a patent litigation case filed in the United States District Court for the District of Delaware, with the case number 1:22-cv-00244. The case involves complex issues of patent ownership, litigation funding, and potential fraud on the court.

Background

Mellaconic IP LLC, a plaintiff, asserted patent infringement claims against TimeClock Plus, LLC. The case is part of a broader set of litigation involving similar plaintiffs and defendants, including other cases filed by Nimitz and Lamplight Licensing LLC[2][4].

Key Issues and Concerns

Several critical issues have emerged in this litigation:

Accuracy of Filings and Representation

The court has raised concerns about the accuracy of statements made by Mellaconic IP LLC in its filings and whether the real parties in interest are before the court. There are suspicions that Mellaconic may have made inaccurate statements and that counsel, including Mr. Chong, may have failed to comply with the Rules of Professional Conduct[2][4].

Hidden Real Parties in Interest

The court suspects that real parties in interest, such as IP Edge and Mavexar, may have been hidden from the court and the defendants. These entities may have fraudulently conveyed patents to shell LLCs to shield themselves from potential liability[2][4].

Fraud on the Court

There is evidence suggesting that Mavexar and its principals may have used Mellaconic and other nominal owners to perpetrate a fraud on the court, the U.S. Patent and Trademark Office (PTO), and numerous defendants. This includes filing fictitious patent assignments to avoid liability[2][4].

Court Orders and Compliance

In response to these concerns, the court issued a Memorandum Order on November 10, 2022, requiring Mellaconic to produce various documents and communications. These include:

  • Documents related to the retention of law firms Sand, Sebolt & Wemow Co., LPA, and The Chong Law Firm, P.A.
  • Communications regarding the formation of Mellaconic, its assets, and potential settlements or dismissals of the cases.
  • Monthly bank account statements for a specified period.
  • A sworn declaration from Hau Bui identifying Mellaconic's assets as of specific dates[1][2].

Mellaconic was ordered to comply with this Memorandum Order by May 10, 2023, after their motion to set it aside was denied[2].

Litigation Funding and Privilege Assertions

The case also touches on the issue of third-party litigation funding (TPLF). Mellaconic argued that the court's order sought to disclose attorney-client privileged communications and attorney work product. However, the court found good reason to doubt these privilege assertions, suggesting that Mavexar, rather than Mellaconic, might be the principal entity involved[2].

Dismissal Attempts

Mellaconic filed notices of voluntary dismissal in both the TimeClock Plus action and the Deputy action, but these did not resolve the underlying issues of potential fraud and misrepresentation[4].

Evidentiary Hearings

The court conducted consolidated evidentiary hearings for cases involving Nimitz, Mellaconic, and Lamplight Licensing LLC. These hearings revealed serious concerns about the conduct of the parties and their counsel, including potential failures to comply with professional conduct rules and the hiding of real parties in interest[2][4].

Implications and Analysis

Ethical and Legal Implications

The case highlights significant ethical and legal issues in patent litigation, particularly the use of shell entities to avoid liability and the potential for fraud on the court. The court's actions underscore the importance of transparency and compliance with legal and ethical standards in litigation.

Impact on Patent Litigation

This case sets a precedent for how courts may address similar issues in future patent litigation. It emphasizes the need for thorough scrutiny of the parties involved and their financial and legal arrangements to prevent fraudulent practices.

Third-Party Litigation Funding

The case also sheds light on the role of third-party litigation funding in patent cases. While TPLF can provide necessary financial support for litigation, it must be transparent and compliant with legal requirements to avoid complicating the litigation process[3].

Key Takeaways

  • Transparency in Litigation: The case stresses the importance of transparency in litigation, particularly in identifying the real parties in interest.
  • Ethical Compliance: Counsel must comply strictly with the Rules of Professional Conduct to avoid ethical violations.
  • Fraud Prevention: Courts are vigilant in preventing fraud on the court, including the use of shell entities to avoid liability.
  • Litigation Funding: Third-party litigation funding must be transparent and compliant with legal standards.

Frequently Asked Questions (FAQs)

Q: What are the main concerns raised by the court in Mellaconic IP LLC v. TimeClock Plus, LLC? A: The court raised concerns about the accuracy of Mellaconic's filings, potential fraud on the court, and the hiding of real parties in interest.

Q: What documents and communications were Mellaconic ordered to produce? A: Mellaconic was ordered to produce documents related to the retention of law firms, communications about the formation and assets of Mellaconic, and monthly bank account statements.

Q: Why did the court deny Mellaconic's motion to set aside the Memorandum Order? A: The court denied the motion because it found good reason to doubt Mellaconic's privilege assertions and needed more information to address concerns about potential fraud.

Q: What is the significance of third-party litigation funding in this case? A: The case highlights the need for transparency in third-party litigation funding to prevent complicating the litigation process and to ensure compliance with legal standards.

Q: What are the potential consequences for Mellaconic and its counsel if the allegations of fraud are proven? A: If proven, the allegations could result in severe legal and ethical consequences, including sanctions, dismissal of the cases, and potential disciplinary action against the counsel involved.

Cited Sources

  1. Mellaconic IP LLC v. Timeclock Plus, LLC, Civ. 22-244-CFC, United States District Court, D. Delaware, Nov 10, 2022.
  2. Mellaconic IP LLC v. Timeclock Plus, LLC, Civ. 22-244-CFC, United States District Court, D. Delaware, May 3, 2023.
  3. Here's How Third-Party Litigation Funders Are Being Addressed by Courts and Policymakers, Baker Botts, July 2024.
  4. Mellaconic IP LLC v. Timeclock Plus, LLC, Civ. 22-244-CFC, Casetext.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.